Share-Based Payments (Tables)

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

Share-based compensation expense included in condensed consolidated statements of income

The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:

	For the Three Months Ended March 31,
(In millions)	2025		2024
Research and development	$	32.1	$	27.4
Selling, general and administrative	52.0		44.0
Subtotal	84.1		71.4
Capitalized share-based compensation costs	(3.1)		(3.3)
Share-based compensation expense included in total cost and expense	81.0		68.1
Income tax effect	(16.0)		(12.9)
Share-based compensation expense included in net income attributable to Biogen Inc.	$	65.0	$	55.2

Summary of share-based compensation expense associated with each of our share-based compensating programs

The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:

	For the Three Months Ended March 31,
(In millions)	2025		2024
Time-vested restricted stock units	$	66.1	$	57.3
Performance stock units settled in stock	13.6		10.5
Employee stock purchase plan	3.5		4.5
Performance stock units settled in cash	—		(2.1)
Stock options	0.9		0.9
Market stock units	—		0.3
Subtotal	84.1		71.4
Capitalized share-based compensation costs	(3.1)		(3.3)
Share-based compensation expense included in total cost and expense	$	81.0	$	68.1